In our exploration of immune features linked to response and resistance to immune checkpoint therapy in glioblastoma patients, we leveraged the CRI iAtlas to scrutinize the immune landscape in individuals treated with anti-PD1 agents, namely, Nivolumab or Pembrolizumab. The gene discussed is PDCD1; the disease is glioblastoma.